Pfizer, Inc.
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
企業詳細臨床日程
銘柄カテゴリー
臨床日程
- 2026年8月23日予定
PFE第1相・第2相がん・腫瘍Active Not Recruiting - 2026年8月26日予定
AMGN第1相心臓・循環器Active Not Recruiting Amgen Inc.
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
企業詳細 - 2026年8月28日予定
AZN第1相・第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
企業詳細 - 2026年8月28日予定
AZN第1相医療機器・ヘルスケアActive Not Recruiting AstraZeneca PLC
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
企業詳細 - 2026年8月30日予定
AZN第1相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Selumetinib and Olaparib in Solid Tumors
企業詳細 - 2026年8月31日予定
AZN第1相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
企業詳細 - 2026年8月31日予定
PFE第1相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
企業詳細 - 2026年9月予定
ABBV第1相がん・腫瘍Active Not Recruiting AbbVie Inc.
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
企業詳細 - 2026年9月予定
ABBV第1相医療機器・ヘルスケアActive Not Recruiting AbbVie Inc.
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
企業詳細 - 2026年9月予定
ABBV第1相医療機器・ヘルスケアRecruiting AbbVie Inc.
A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants
企業詳細 - 2026年9月予定
ABBV第1相医療機器・ヘルスケアRecruiting AbbVie Inc.
A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants
企業詳細 - 2026年9月予定
AZN第1相・第2相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
企業詳細 - 2026年9月予定
AZN第1相がん・腫瘍Active Not Recruiting AstraZeneca PLC
Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma
企業詳細 - 2026年9月予定
AZN第1相・第2相がん・腫瘍Recruiting AstraZeneca PLC
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
企業詳細 - 2026年9月予定
LLY第1相医療機器・ヘルスケアRecruiting Eli Lilly and Company
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
企業詳細 - 2026年9月予定
LLY第1相医療機器・ヘルスケアActive Not Recruiting Eli Lilly and Company
A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants
企業詳細 - 2026年9月予定
LNTH第1相心臓・循環器Recruiting Lantheus Holdings, Inc.
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
企業詳細 - 2026年9月予定
MRK第1相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
企業詳細 - 2026年9月1日予定
PFE第1相・第2相がん・腫瘍Active Not Recruiting Pfizer, Inc.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
企業詳細 - 2026年9月2日予定
MRK第1相医療機器・ヘルスケアActive Not Recruiting Merck & Company, Inc.
A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
企業詳細 - 2026年9月3日予定
AMGN第1相医療機器・ヘルスケアActive Not Recruiting Amgen Inc.
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
企業詳細 - 2026年9月3日予定
AZN第1相脳・神経・睡眠Active Not Recruiting AstraZeneca PLC
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
企業詳細 - 2026年9月3日予定
MRK第1相糖尿病・代謝Active Not Recruiting Merck & Company, Inc.
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
企業詳細 - 2026年9月3日予定
MRK第1相医療機器・ヘルスケアActive Not Recruiting Merck & Company, Inc.
A Study of MK-7240 in Healthy Participants (MK-7240-009)
企業詳細 - 2026年9月3日予定
NVO第1相糖尿病・代謝Active Not Recruiting Novo Nordisk A/S
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
企業詳細 - 2026年9月3日予定
PFE第1相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
企業詳細 - 2026年9月5日予定
MRK第1相医療機器・ヘルスケアActive Not Recruiting Merck & Company, Inc.
A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
企業詳細 - 2026年9月7日予定
AZN第1相医療機器・ヘルスケアActive Not Recruiting AstraZeneca PLC
A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults
企業詳細 - 2026年9月10日予定
PFE第1相医療機器・ヘルスケアNot Yet Recruiting Pfizer, Inc.
A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults
企業詳細 - 2026年9月12日予定
NVO第1相糖尿病・代謝Active Not Recruiting Novo Nordisk A/S
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
企業詳細 - 2026年9月12日予定
PFE第1相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women
企業詳細 - 2026年9月14日予定
MRK第1相感染症・ワクチンActive Not Recruiting Merck & Company, Inc.
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
企業詳細 - 2026年9月15日予定
PFE第1相・第2相医療機器・ヘルスケアRecruiting Pfizer, Inc.
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
企業詳細 - 2026年9月17日予定
AZN第1相医療機器・ヘルスケアActive Not Recruiting AstraZeneca PLC
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
企業詳細 - 2026年9月21日予定
MRK第1相感染症・ワクチンRecruiting Merck & Company, Inc.
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
企業詳細 - 2026年9月22日予定
MRK第1相医療機器・ヘルスケアRecruiting Merck & Company, Inc.
A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)
企業詳細 - 2026年9月23日予定
AZN第1相医療機器・ヘルスケアRecruiting AstraZeneca PLC
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
企業詳細 - 2026年9月28日予定
MRK第1相医療機器・ヘルスケアRecruiting Merck & Company, Inc.
A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)
企業詳細 - 2026年9月30日予定
MRK第1相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
企業詳細 - 2026年9月30日予定
MRK第1相・第2相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
企業詳細 - 2026年9月30日予定
MRK第1相・第2相がん・腫瘍Recruiting Merck & Company, Inc.
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
企業詳細 - 2026年9月30日予定
MRK第1相がん・腫瘍Active Not Recruiting Merck & Company, Inc.
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
企業詳細 - 2026年9月30日予定
MRK第1相医療機器・ヘルスケアRecruiting Merck & Company, Inc.
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
企業詳細 - 2026年10月予定
CRNX第1相・第2相糖尿病・代謝Active Not Recruiting Crinetics Pharmaceuticals, Inc.
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
企業詳細 - 2026年10月予定
IMCR第1相・第2相がん・腫瘍Active Not Recruiting Immunocore Holdings plc
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
企業詳細 - 2026年10月予定
LLY第1相糖尿病・代謝Active Not Recruiting Eli Lilly and Company
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
企業詳細
